Adagene (ADAG) Projected to Post Quarterly Earnings on Monday

Adagene (NASDAQ:ADAG) will likely be posting its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 1:30 PM ET.

Adagene Trading Down 1.6%

Shares of Adagene stock opened at $3.63 on Friday. Adagene has a 52-week low of $1.30 and a 52-week high of $4.58. The company has a 50 day moving average of $2.88 and a 200 day moving average of $2.25.

Analyst Upgrades and Downgrades

ADAG has been the subject of a number of research reports. Wall Street Zen raised shares of Adagene to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adagene in a report on Wednesday, January 21st. Finally, Guggenheim began coverage on Adagene in a report on Monday, November 24th. They issued a “buy” rating and a $9.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $7.67.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Marex Group plc purchased a new stake in shares of Adagene during the second quarter valued at approximately $47,000. SmartHarvest Portfolios LLC bought a new stake in shares of Adagene in the 4th quarter worth about $73,000. Citadel Advisors LLC acquired a new stake in Adagene during the third quarter valued at approximately $80,000. Finally, Exome Asset Management LLC acquired a new stake in shares of Adagene during the 4th quarter valued at approximately $2,004,000. 9.51% of the stock is owned by hedge funds and other institutional investors.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.